308 related articles for article (PubMed ID: 30388618)
1. NS-065/NCNP-01: An Antisense Oligonucleotide for Potential Treatment of Exon 53 Skipping in Duchenne Muscular Dystrophy.
Watanabe N; Nagata T; Satou Y; Masuda S; Saito T; Kitagawa H; Komaki H; Takagaki K; Takeda S
Mol Ther Nucleic Acids; 2018 Dec; 13():442-449. PubMed ID: 30388618
[TBL] [Abstract][Full Text] [Related]
2. Exon 44 skipping in Duchenne muscular dystrophy: NS-089/NCNP-02, a dual-targeting antisense oligonucleotide.
Watanabe N; Tone Y; Nagata T; Masuda S; Saito T; Motohashi N; Takagaki K; Aoki Y; Takeda S
Mol Ther Nucleic Acids; 2023 Dec; 34():102034. PubMed ID: 37854955
[TBL] [Abstract][Full Text] [Related]
3. Direct Reprogramming of Human DMD Fibroblasts into Myotubes for In Vitro Evaluation of Antisense-Mediated Exon Skipping and Exons 45-55 Skipping Accompanied by Rescue of Dystrophin Expression.
Lee JJA; Saito T; Duddy W; Takeda S; Yokota T
Methods Mol Biol; 2018; 1828():141-150. PubMed ID: 30171539
[TBL] [Abstract][Full Text] [Related]
4. Systemic administration of the antisense oligonucleotide NS-065/NCNP-01 for skipping of exon 53 in patients with Duchenne muscular dystrophy.
Komaki H; Nagata T; Saito T; Masuda S; Takeshita E; Sasaki M; Tachimori H; Nakamura H; Aoki Y; Takeda S
Sci Transl Med; 2018 Apr; 10(437):. PubMed ID: 29669851
[TBL] [Abstract][Full Text] [Related]
5. Quantitative Antisense Screening and Optimization for Exon 51 Skipping in Duchenne Muscular Dystrophy.
Echigoya Y; Lim KRQ; Trieu N; Bao B; Miskew Nichols B; Vila MC; Novak JS; Hara Y; Lee J; Touznik A; Mamchaoui K; Aoki Y; Takeda S; Nagaraju K; Mouly V; Maruyama R; Duddy W; Yokota T
Mol Ther; 2017 Nov; 25(11):2561-2572. PubMed ID: 28865998
[TBL] [Abstract][Full Text] [Related]
6. Restoring Dystrophin Expression with Exon 44 and 53 Skipping in the DMD Gene in Immortalized Myotubes.
Echigoya Y; Yokota T
Methods Mol Biol; 2023; 2587():125-139. PubMed ID: 36401027
[TBL] [Abstract][Full Text] [Related]
7. In Vitro Multiexon Skipping by Antisense PMOs in Dystrophic Dog and Exon 7-Deleted DMD Patient.
Nakamura A; Aoki Y; Tsoumpra M; Yokota T; Takeda S
Methods Mol Biol; 2018; 1828():151-163. PubMed ID: 30171540
[TBL] [Abstract][Full Text] [Related]
8. Antisense Oligonucleotide Treatment in a Humanized Mouse Model of Duchenne Muscular Dystrophy and Highly Sensitive Detection of Dystrophin Using Western Blotting.
Maruyama R; Yokota T
Methods Mol Biol; 2021; 2224():203-214. PubMed ID: 33606217
[TBL] [Abstract][Full Text] [Related]
9. Highly sensitive screening of antisense sequences for different types of DMD mutations in patients' urine-derived cells.
Takizawa H; Takeshita E; Sato M; Shimizu-Motohashi Y; Ishiyama A; Mori-Yoshimura M; Takahashi Y; Komaki H; Aoki Y
J Neurol Sci; 2021 Apr; 423():117337. PubMed ID: 33610829
[TBL] [Abstract][Full Text] [Related]
10. Systemic administration of the antisense oligonucleotide NS-089/NCNP-02 for skipping of exon 44 in patients with Duchenne muscular dystrophy: Study protocol for a phase I/II clinical trial.
Ishizuka T; Komaki H; Asahina Y; Nakamura H; Motohashi N; Takeshita E; Shimizu-Motohashi Y; Ishiyama A; Yonee C; Maruyama S; Hida E; Aoki Y
Neuropsychopharmacol Rep; 2023 Jun; 43(2):277-286. PubMed ID: 37326950
[TBL] [Abstract][Full Text] [Related]
11. Creation of DMD Muscle Cell Model Using CRISPR-Cas9 Genome Editing to Test the Efficacy of Antisense-Mediated Exon Skipping.
Maruyama R; Yokota T
Methods Mol Biol; 2018; 1828():165-171. PubMed ID: 30171541
[TBL] [Abstract][Full Text] [Related]
12. Viltolarsen for the treatment of Duchenne muscular dystrophy.
Roshmi RR; Yokota T
Drugs Today (Barc); 2019 Oct; 55(10):627-639. PubMed ID: 31720560
[TBL] [Abstract][Full Text] [Related]
13. Immortalized Muscle Cell Model to Test the Exon Skipping Efficacy for Duchenne Muscular Dystrophy.
Nguyen Q; Yokota T
J Pers Med; 2017 Oct; 7(4):. PubMed ID: 29035327
[TBL] [Abstract][Full Text] [Related]
14. Exons 45-55 Skipping Using Mutation-Tailored Cocktails of Antisense Morpholinos in the DMD Gene.
Echigoya Y; Lim KRQ; Melo D; Bao B; Trieu N; Mizobe Y; Maruyama R; Mamchaoui K; Tanihata J; Aoki Y; Takeda S; Mouly V; Duddy W; Yokota T
Mol Ther; 2019 Nov; 27(11):2005-2017. PubMed ID: 31416775
[TBL] [Abstract][Full Text] [Related]
15.
Goossens R; Verwey N; Ariyurek Y; Schnell F; Aartsma-Rus A
RNA Biol; 2023 Jan; 20(1):693-702. PubMed ID: 37667454
[TBL] [Abstract][Full Text] [Related]
16. Multiple Exon Skipping in the Duchenne Muscular Dystrophy Hot Spots: Prospects and Challenges.
Echigoya Y; Lim KRQ; Nakamura A; Yokota T
J Pers Med; 2018 Dec; 8(4):. PubMed ID: 30544634
[TBL] [Abstract][Full Text] [Related]
17. Designing Effective Antisense Oligonucleotides for Exon Skipping.
Shimo T; Maruyama R; Yokota T
Methods Mol Biol; 2018; 1687():143-155. PubMed ID: 29067661
[TBL] [Abstract][Full Text] [Related]
18. Tips to Design Effective Splice-Switching Antisense Oligonucleotides for Exon Skipping and Exon Inclusion.
Maruyama R; Yokota T
Methods Mol Biol; 2018; 1828():79-90. PubMed ID: 30171536
[TBL] [Abstract][Full Text] [Related]
19. A novel human muscle cell model of Duchenne muscular dystrophy created by CRISPR/Cas9 and evaluation of antisense-mediated exon skipping.
Shimo T; Hosoki K; Nakatsuji Y; Yokota T; Obika S
J Hum Genet; 2018 Mar; 63(3):365-375. PubMed ID: 29339778
[TBL] [Abstract][Full Text] [Related]
20. Exon Skipping Therapy Using Phosphorodiamidate Morpholino Oligomers in the mdx52 Mouse Model of Duchenne Muscular Dystrophy.
Miyatake S; Mizobe Y; Takizawa H; Hara Y; Yokota T; Takeda S; Aoki Y
Methods Mol Biol; 2018; 1687():123-141. PubMed ID: 29067660
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
